Compare · ABBV vs AMPH
ABBV vs AMPH
Side-by-side comparison of AbbVie Inc. (ABBV) and Amphastar Pharmaceuticals Inc. (AMPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and AMPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $243.83B, about 195.5x AMPH ($1.25B).
- Over the past year, ABBV is up 3.3% and AMPH is down 12.1% - ABBV leads by 15.4 points.
- ABBV has been more active in the news (9 items in the past 4 weeks vs 4 for AMPH).
- ABBV has more recent analyst coverage (25 ratings vs 13 for AMPH).
- Company
- AbbVie Inc.
- Amphastar Pharmaceuticals Inc.
- Price
- $198.71-1.12%
- $21.44+2.05%
- Market cap
- $243.83B
- $1.25B
- 1M return
- -4.09%
- +9.61%
- 1Y return
- +3.29%
- -12.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2014
- News (4w)
- 9
- 4
- Recent ratings
- 25
- 13
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as manufactures and distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Latest ABBV
- AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
- AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
- Canaccord Genuity initiated coverage on AbbVie with a new price target
- AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada
- Erin Lichy Gets Real About Her Natrelle® Breast Augmentation
- Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
- AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
- BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year
- Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest AMPH
- Amphastar Pharmaceuticals downgraded by Jefferies with a new price target
- SEC Form DEFA14A filed by Amphastar Pharmaceuticals Inc.
- SEC Form DEF 14A filed by Amphastar Pharmaceuticals Inc.
- Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Amphastar Pharmaceuticals Inc.
- EVP CORP ADMIN CENTER Liawatidewi Yakob covered exercise/tax liability with 1,033 shares, decreasing direct ownership by 0.84% to 121,892 units (SEC Form 4)
- SENIOR EVP, PRODUCTION CENTER Zhou Rong covered exercise/tax liability with 1,225 shares, decreasing direct ownership by 0.71% to 171,554 units (SEC Form 4)
- CFO, EVP & TREASURER Peters William J covered exercise/tax liability with 1,973 shares, decreasing direct ownership by 1% to 175,063 units (SEC Form 4)
- CEO & CHIEF SCIENTIFIC OFFICER Zhang Jack Y. covered exercise/tax liability with 12,692 shares, decreasing direct ownership by 0.33% to 2,990,052 units (SEC Form 4)
- Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Other Events